Here is our Top Docs 2025 profile on Jeffrey Zonder, M.D., who is part of the Karmanos Cancer Institute’s Multiple Myeloma and Amyloidosis Multidisciplinary Team.
Bouchard opened a discussion on sequencing therapies in MM, noting that CAR T-cell therapy and bispecific antibodies each ...
A dexamethasone-sparing regimen involving lenalidomide (Revlimid) and the anti-CD38 drug daratumumab (Darzalex) was safe and ...
Cevostamab showed a 93% MRD-negative complete response rate at 1 year post CAR T-cell therapy in heavily pretreated multiple ...
At a median follow-up of 39.4 months, results from the second interim analysis showed a sustained and significant OS benefit with BVd compared to DVd.
As September concludes, the landscape of hematologic oncology continues to evolve, spanning the full spectrum of blood cancer ...
A multinational biopharmaceutical corporation, Bristol-Myers Squibb Company (NYSE:BMY) is engaged in product discovery, ...
At a live event in White Plains, New York, Adriana Rossi, MD, assistant professor of medicine and director of CAR T and the Stem Cell Transplant Clinical Service at the Center of Excellence for ...
Long-term remission in multiple myeloma—a blood cancer once considered incurable—is finally becoming a reality. A single ...
Although multiple myeloma is often considered incurable, the development of highly effective new therapies is creating a real possibility of a cure for some patients. Current 4-drug upfront regimens, ...
Background aims: Chimeric antigen receptor (CAR) T-cell therapy shows remarkable efficacy against relapsed/refractory multiple myeloma (R/R MM). Nutritional status, assessed by objective indices like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback